The United States represents a significant share of the Choroidal Neovascularization Market, driven by the high prevalence of age-related macular degeneration (AMD) and other retinal disorders among its growing elderly population. The country's advanced healthcare infrastructure, strong reimbursement policies, and widespread adoption of anti-VEGF therapies support market expansion. Furthermore,...